Frank I Scott1, Ravy K Vajravelu2, Meenakshi Bewtra3, Ronac Mamtani3, Dale Lee4, David S Goldberg3, James D Lewis3. 1. Division of Gastroenterology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: frankis@mail.med.upenn.edu. 2. Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 3. Division of Gastroenterology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 4. Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Division of Gastroenterology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Abstract
BACKGROUND & AIMS: Combination therapy with infliximab and azathioprine has demonstrated benefit over monotherapy for moderate-to-severe Crohn's disease. Clinical trials and models have not accounted for age-specific risks associated with these therapies, including the risk of immunosuppression-related cancer and infection. After accounting for these risks, the strategy yielding the greatest benefit may vary with age. METHODS: We assessed age-specific risks and benefits of combination therapy compared with infliximab monotherapy by using Markov modeling. The base case was a 35-year-old male patient with a 1-year time horizon. We assumed the incidence of lymphoma to be 5.28-fold higher with combination therapy. Secondary analyses accounted for life expectancy, therapy beyond 1 year, and age-specific surgical and infection risks. Quality-adjusted life years (QALYs) were calculated for 25- to 75-year old individuals. RESULTS: Combination therapy was found to be of greater benefit in the base case (0.7522 QALYs for combination therapy vs 0.7426 QALYs for monotherapy). Accounting for life years lost, monotherapy was the best approach if the hazard ratio for lymphoma with combination therapy was >8.1 patients who were 75 years old. Monotherapy provided greater net benefit to patients 55, 65, or 75 years old if therapy was extended for 9, 7, or 5 years, respectively. For 25-year-old men, monotherapy resulted in fewer deaths but only yielded greater QALYs if the annual incidence of hepatosplenic T-cell lymphoma exceeded 36/100,000 persons. CONCLUSIONS: After accounting for age-specific risks of lymphoma, infection, and surgical complications, benefits of combination therapy outweighed the risks as a short-term and intermediate-term strategy for most patients with moderate-to-severe Crohn's disease who were younger than 65 years. For young male patients, combination therapy yields greater QALYs but at cost of an increased risk of death from lymphoma.
BACKGROUND & AIMS: Combination therapy with infliximab and azathioprine has demonstrated benefit over monotherapy for moderate-to-severe Crohn's disease. Clinical trials and models have not accounted for age-specific risks associated with these therapies, including the risk of immunosuppression-related cancer and infection. After accounting for these risks, the strategy yielding the greatest benefit may vary with age. METHODS: We assessed age-specific risks and benefits of combination therapy compared with infliximab monotherapy by using Markov modeling. The base case was a 35-year-old male patient with a 1-year time horizon. We assumed the incidence of lymphoma to be 5.28-fold higher with combination therapy. Secondary analyses accounted for life expectancy, therapy beyond 1 year, and age-specific surgical and infection risks. Quality-adjusted life years (QALYs) were calculated for 25- to 75-year old individuals. RESULTS: Combination therapy was found to be of greater benefit in the base case (0.7522 QALYs for combination therapy vs 0.7426 QALYs for monotherapy). Accounting for life years lost, monotherapy was the best approach if the hazard ratio for lymphoma with combination therapy was >8.1 patients who were 75 years old. Monotherapy provided greater net benefit to patients 55, 65, or 75 years old if therapy was extended for 9, 7, or 5 years, respectively. For 25-year-old men, monotherapy resulted in fewer deaths but only yielded greater QALYs if the annual incidence of hepatosplenic T-cell lymphoma exceeded 36/100,000 persons. CONCLUSIONS: After accounting for age-specific risks of lymphoma, infection, and surgical complications, benefits of combination therapy outweighed the risks as a short-term and intermediate-term strategy for most patients with moderate-to-severe Crohn's disease who were younger than 65 years. For young male patients, combination therapy yields greater QALYs but at cost of an increased risk of death from lymphoma.
Authors: Carlos G Grijalva; Lang Chen; Elizabeth Delzell; John W Baddley; Timothy Beukelman; Kevin L Winthrop; Marie R Griffin; Lisa J Herrinton; Liyan Liu; Rita Ouellet-Hellstrom; Nivedita M Patkar; Daniel H Solomon; James D Lewis; Fenglong Xie; Kenneth G Saag; Jeffrey R Curtis Journal: JAMA Date: 2011-11-06 Impact factor: 56.272
Authors: Jean-Frédéric Colombel; William J Sandborn; Paul Rutgeerts; Robert Enns; Stephen B Hanauer; Remo Panaccione; Stefan Schreiber; Dan Byczkowski; Ju Li; Jeffrey D Kent; Paul F Pollack Journal: Gastroenterology Date: 2006-11-29 Impact factor: 22.682
Authors: Jean Frédéric Colombel; William J Sandborn; Walter Reinisch; Gerassimos J Mantzaris; Asher Kornbluth; Daniel Rachmilewitz; Simon Lichtiger; Geert D'Haens; Robert H Diamond; Delma L Broussard; Kezhen L Tang; C Janneke van der Woude; Paul Rutgeerts Journal: N Engl J Med Date: 2010-04-15 Impact factor: 91.245
Authors: Hossein Masoomi; Celeste Y Kang; Obaid Chaudhry; Alessio Pigazzi; Steven Mills; Joseph C Carmichael; Michael J Stamos Journal: J Am Coll Surg Date: 2012-03-28 Impact factor: 6.113
Authors: Rebecca L Olin; Peter A Kanetsky; Thomas R Ten Have; Sunita D Nasta; Stephen J Schuster; Charalambos Andreadis Journal: Am J Hematol Date: 2010-04 Impact factor: 10.047
Authors: Nabeel Khan; Ali M Abbas; Gary R Lichtenstein; Edward V Loftus; Lydia A Bazzano Journal: Gastroenterology Date: 2013-07-25 Impact factor: 22.682
Authors: Meenakshi Bewtra; Angelyn O Fairchild; Erin Gilroy; David A Leiman; Caroline Kerner; F Reed Johnson; James D Lewis Journal: Am J Gastroenterol Date: 2015-10-20 Impact factor: 10.864
Authors: Meenakshi Bewtra; Craig W Newcomb; Qufei Wu; Lang Chen; Fenglong Xie; Jason A Roy; Cary B Aarons; Mark T Osterman; Kimberly A Forde; Jeffrey R Curtis; James D Lewis Journal: Ann Intern Med Date: 2015-08-18 Impact factor: 25.391
Authors: Edward Shelton; David Laharie; Frank I Scott; Ronac Mamtani; James D Lewis; Jean-Frederic Colombel; Ashwin N Ananthakrishnan Journal: Gastroenterology Date: 2016-04-01 Impact factor: 22.682